Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Quadriplex model enhances urine-based detection of prostate cancer

Prostate Cancer and Prostatic Diseases volume 14, pages 354–360 (2011)Cite this article

Subjects

Abstract

Background:

The major advantages of urine-based assays are their non-invasive character and ability to monitor prostate cancer (CaP) with heterogeneous foci. While the test for the prostate cancer antigen 3 (PCA3) is commercially available, the aim of our research was to test other putative urine markers in multiplex settings (AMACR (α-methylacyl-CoA racemase), EZH2 (enhancer of zeste homolog 2), GOLM1 (golgi membrane protein 1), MSMB (microseminoprotein, β), SPINK1 (serine peptidase inhibitor) and TRPM8 (transient receptor potential cation channel, subfamily M, member 8)).

Methods:

Expression of the candidate biomarkers was studied in sedimented urine using quantitative reverse transcriptase polymerase chain reaction in two sets of patients with and without restriction on serum PSA levels.

Results:

We confirmed that PCA3 is an independent predictor of cancer in the patients without restriction of serum PSA values (set 1, n=176, PSA=0.1–587 ng ml–1). However, AMACR was the only parameter that differentiated CaP from non-CaP patients with serum PSA between 3 and 15 ng ml–1 (set 2, n=104). The area under curve (AUC) for this gene was 0.645 with both sensitivity and specificity at 65%. Further improvement was achieved by multivariate logistic regression analysis, which identified novel duplex (TRPM8 and MSMB), triplex (plus AMACR) and quadriplex (plus PCA3) models for the detection of early CaPs (AUC=0.665, 0.726 and 0.741, respectively).

Conclusions:

Novel quadriplex test could be implemented as an adjunct to serum PSA or urine PCA3 and this could improve decision making for diagnostics in the case of ‘PSA dilemma’ patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, Lilja H et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 2005; 48: 1031–1041.

    Article  CAS  PubMed  Google Scholar 

  2. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005; 114: 950–956.

    Article  CAS  PubMed  Google Scholar 

  3. Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006; 66: 1521–1534.

    Article  CAS  PubMed  Google Scholar 

  4. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006; 8: 885–888.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008; 68: 645–649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Schneider S, Voigt S, Fussel S, Lohse-Fischer A, Tomasetti S, Haase M et al. [Molecular genetic markers for prostate cancer. Evidence in fine needle biopsies for improved confirmation of the diagnosis]. Urologe A 2008; 47: 1208–1211.

    Article  CAS  PubMed  Google Scholar 

  7. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM . A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009; 181: 2508–2513; discussion 2513–2514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Noutsias M, Rohde M, Block A, Klippert K, Lettau O, Blunert K et al. Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Mol Biol 2008; 9: 3.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pfaffl MW . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR . Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract 2002; 3: 19.

    Article  PubMed  PubMed Central  Google Scholar 

  11. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007; 13: 939–943.

    Article  CAS  PubMed  Google Scholar 

  12. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532–535.

    Article  PubMed  Google Scholar 

  13. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081–1088.

    Article  PubMed  Google Scholar 

  14. Thompson IM, Ankerst DP . Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176: 1853–1858.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 2004; 172: 1501–1503.

    Article  CAS  PubMed  Google Scholar 

  16. Prior C, Guillen-Grima F, Robles JE, Rosell D, Fernandez-Montero JM, Agirre X et al. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol 2010; 28: 681–686.

    Article  CAS  PubMed  Google Scholar 

  17. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13: 519–528.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008; 10: 1285–1294.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zhang L, Barritt GJ . TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function? Endocr Relat Cancer 2006; 13: 27–38.

    Article  PubMed  Google Scholar 

  20. Bai VU, Murthy S, Chinnakannu K, Muhletaler F, Tejwani S, Barrack ER et al. Androgen regulated TRPM8 expression: a potential mRNA marker for metastatic prostate cancer detection in body fluids. Int J Oncol 2010; 36: 443–450.

    CAS  PubMed  Google Scholar 

  21. Teni TR, Sheth AR, Kamath MR, Sheth NA . Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett 1988; 43: 9–14.

    Article  CAS  PubMed  Google Scholar 

  22. Tsurusaki T, Koji T, Sakai H, Kanetake H, Nakane PK, Saito Y . Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998; 35: 109–116.

    Article  CAS  PubMed  Google Scholar 

  23. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE . The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010; 70: 333–340.

    CAS  PubMed  Google Scholar 

  24. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H et al. alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002; 161: 841–848.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005; 14: 1424–1432.

    Article  CAS  PubMed  Google Scholar 

  26. Nguyen PN, Violette P, Chan S, Tanguay S, Kassouf W, Aprikian A et al. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol 2011; 59: 407–414.

    Article  CAS  PubMed  Google Scholar 

  27. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T . The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006; 45: 639–645.

    Article  CAS  PubMed  Google Scholar 

  28. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624–629.

    Article  CAS  PubMed  Google Scholar 

  29. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H . Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419–429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by Grants NS 9940-4 from the Czech Ministry of Health and MSM 6198959216 from the Czech Ministry of Education and EU infrastructure support CZ.1.05/2.1.00/01.0030. Tamar Jamaspishvili was also supported by GACR 303/09/H048 from the Grant Agency of the Czech Republic and LF_2010_006. We sincerely thank Jana Holinkova for her excellent technical assistance.

Author information

Authors and Affiliations

  1. Department of Clinical and Molecular Pathology, Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic

    T Jamaspishvili, G Mgebrishvili, Z Kolar & J Bouchal

  2. Department of Urology, University Hospital, Olomouc, Czech Republic

    M Kral, I Khomeriki, V Vyhnankova & V Student

Authors
  1. T Jamaspishvili
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kral
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Khomeriki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Vyhnankova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Mgebrishvili
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Student
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z Kolar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Bouchal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Bouchal.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jamaspishvili, T., Kral, M., Khomeriki, I. et al. Quadriplex model enhances urine-based detection of prostate cancer. Prostate Cancer Prostatic Dis 14, 354–360 (2011). https://doi.org/10.1038/pcan.2011.32

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.32

Keywords

This article is cited by

Search

Advanced search

Quick links